Pricing Log in Create free account

Arvinas, Inc. (ARVN) vs Autolus Therapeutics PLC Sponsored ADR (AUTL)

Arvinas, Inc. and Autolus Therapeutics PLC Sponsored ADR are both Biotechnology companies. Arvinas, Inc. and Autolus Therapeutics PLC Sponsored ADR are of similar size ($468.2M and $457.8M). Autolus Therapeutics PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Arvinas, Inc. trades at 53.6×. Autolus Therapeutics PLC Sponsored ADR grew revenue faster over the last twelve months: 193.3% against −15.1%. Arvinas, Inc. has the higher net margin (2.94% vs −238.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Arvinas, Inc. leads on 14 and Autolus Therapeutics PLC Sponsored ADR on 3.

Valuation

Metric ARVN AUTL Biotechnology median
P/E 53.62 n/m 8.50
P/S 1.43 3.63 9.71
P/B 0.80 5.69 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 6.41 n/m 0.64
EV/Sales (0.36) 2.56 9.21
Earnings yield 1.87% (66.25%) (33.15%)
Free cash flow yield (46.23%) (59.62%) (25.50%)

Profitability

Metric ARVN AUTL Biotechnology median
Gross margin 97.16% 15.66% 65.16%
Operating margin (5.72%) (210.78%) 0.00%
Net margin 2.94% (238.66%) 0.00%
Free cash flow margin (65.93%) (198.26%) 0.00%
Return on equity 1.59% (133.00%) (56.36%)
Return on assets 1.17% (46.15%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARVN AUTL Biotechnology median
Revenue growth (TTM) (15.05%) 193.29% 6.02%
EPS growth (last fiscal year) 58.84% (25.58%) 30.26%
Revenue growth, 5-year CAGR 58.93% 113.11% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARVN AUTL Biotechnology median
Debt to equity 0.00 1.04 0.00
Current ratio 7.91 4.89 4.72
Net debt to EBITDA 5.62 1.16 0.96

Dividend

Metric ARVN AUTL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ARVN AUTL Biotechnology median
Market cap 468.16m 457.80m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack